Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience
Wei Sun,
Ai-Bin Liang,
He Huang,
Xiao-Jun Huang
Affiliations
Wei Sun
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, People's Republic of China
Ai-Bin Liang
Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China
He Huang
Bone Marrow Transplantation Center, Institute of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China
Xiao-Jun Huang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, People's Republic of China
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising form of adoptive T-cell immunotherapy for selected hematologic malignancies including leukemia, lymphoma and multiple myeloma. China has become the country with the largest number of registered CAR T-cell trials. Despite the remarkable clinical outcomes achieved with CAR Tcell therapy, challenges such as disease relapse, the process of manufacturing the CAR T cells and safety have limited the therapeutic efficacy of CAR T cells in hematologic malignancies. In this period of innovation, several clinical trials have reported the design of CAR directed at new targets in hematologic malignancies. In this review, we comprehensively summarize the contemporary landscape and clinical development of CAR T-cell therapy in China. In addition, we present strategies for further improving the clinical utility of CAR T-cell therapy, such as increasing the efficacy and response duration, in hematologic malignancies.
